EMBC Shareholder Alert: August 17, 2026 Lead Plaintiff Deadline in Embecta Corp. Securities Class Action - Contact Levi & Korsinsky

BTIG downgraded Embecta Corp. from Buy to Neutral. Wolfe Research titled its coverage note "Ouch! Injection of FY2Q26 Info Stings. US Needs a Bandaid." Fiscal year 2026 EPS guidance was slashed approximately 40%. Shares lost $5.35 in a single trading session.

These analyst reactions followed Embecta's May 5, 2026 disclosure that its U.S. business had deteriorated far beyond anything management had signaled to the market during the Class Period of November 25, 2025 through May 4, 2026.

Embecta's stock closed at $9.25 on May 4, 2026, and fell to $3.90 the following day after second quarter results revealed revenue down 17.4% on an adjusted constant currency basis.

Analyst coverage heading into the Class Period reflected the confidence Embecta's leadership projected. At the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, the Company described its pen needle franchise as "incredibly resolute" and highlighted stable insulin pen prescription trends. On February 5, 2026, the Company reaffirmed all fiscal year 2026 guidance ranges, including revenue of $1.071 billion to $1.093 billion and adjusted EPS of $2.80 to $3.00. Sell-side models, the lawsuit contends, were calibrated to these representations.

The May 5, 2026 earnings release shattered those models: BTIG characterized the quarter as a "major miss" and "guidance cut," downgrading EMBC from Buy to Neutral Wolfe Research noted EMBC was trading at approximately 2.5x fiscal year 2026 earnings following the collapse, with U.S. underperformance and pen needle share loss identified as the primary negative drivers Revised EPS guidance of $1.55 to $1.75 represented an approximately 40% reduction from the $2.80 to $3.00 range management had reaffirmed just three months earlier Adjusted operating margin guidance fell from 29%-30% to 22.25%-23.25%, a contraction of nearly 700 basis points at the midpoint Free cash flow expectations were cut nearly in half, from $180M-$200M to $95M-$105M The Company simultaneously slashed its quarterly dividend from $0.15 to $0.01 per share

The speed and severity of the analyst reassessment reflected how far actual results diverged from what the Company had communicated. As alleged in the securities action filed in the United States District Court for the District of New Jersey, management knew or recklessly disregarded that U.S. pen needle weakness, concentrated share loss at a single customer, and shifting patient purchasing patterns toward channels where Embecta does not participate were undermining the guidance it continued to reaffirm publicly. Wolfe Research's note specifically flagged "share loss in pen needles" and "overall market volume softness" as the largest contributors to the negative surprise. The complaint asserts these were not sudden developments but trends that were observable internally well before the May 5 corrective disclosure.